Center for Pulmonary Diseases, National Hospital Organization, Tokyo National Hospital, 3-1-1 Takeoka, Kiyose, Tokyo, 204-8585, Japan.
J Infect Chemother. 2013 Aug;19(4):579-87. doi: 10.1007/s10156-012-0517-1. Epub 2012 Nov 22.
The Japanese guidelines for nursing- and healthcare-associated pneumonia (NHCAP) categorize patients by risk of resistant bacteria and defined antimicrobials to be used, similar to the healthcare-associated pneumonia (HCAP) guidelines of the United States. The data were collected in large-scale hospitals, possibly a cause of inconsistency with everyday practice in medium-sized community hospitals. To test the feasibility of this guideline based on a retrospective study performed in a medium-sized community hospital in Japan, the medical records of pneumonia patients were retrospectively studied [718 patients: NHCAP, 477, 66.4 %; community-acquired pneumonia (CAP), 241, 33.4 %). Factors related to patients' background, clinical and laboratory findings, treatment, and outcome were compared between NHCAP and CAP. The A-DROP system, scored by age, dehydration, respiratory failure, disorientation, and low blood pressure, evaluated the severity of pneumonia. In contrast to CAP patients, NHCAP patients included more elderly patients requiring nursing care and revealed higher rates of poor nutrition, dementia, aspiration, severe cases, detection of drug-resistant bacteria, and mortality. For NHCAP, the success rate did not differ between those receiving and not receiving proper initial treatment (76.9 vs. 78.5 %) nor did mortality rate within 30 days differ (13.1 vs. 13.8 %). Risk factors for mortality within 30 days for NHCAP were diabetes [adjusted odds ratio (AOR) 2.394, p = 0.009], albumin <2.5 g/dl (AOR 2.766, p = 0.002), A-DROP very severe (AOR 1.930, p = 0.021), and imaging showing extensive pneumonia (AOR 2.541, p = 0.002). The severity of pneumonia rather than risk of resistant bacteria should be considered, in addition to ethical concerns, in initial treatment strategy in NHCAP to avoid excessive use of broad-spectrum antimicrobials.
日本的护理和医疗保健相关性肺炎(NHCAP)指南根据耐药菌的风险对患者进行分类,并定义了要使用的抗菌药物,类似于美国的医疗保健相关性肺炎(HCAP)指南。这些数据是在大型医院收集的,这可能是与中型社区医院日常实践不一致的原因。为了基于日本中型社区医院的回顾性研究来检验该指南的可行性,回顾性研究了肺炎患者的病历[718 例患者:NHCAP,477 例,66.4%;社区获得性肺炎(CAP),241 例,33.4%]。比较了 NHCAP 和 CAP 患者的背景、临床和实验室发现、治疗和结局相关因素。A-DROP 系统根据年龄、脱水、呼吸衰竭、定向障碍和低血压评分,评估肺炎的严重程度。与 CAP 患者相比,NHCAP 患者包括更多需要护理的老年患者,并且营养不良、痴呆、吸入、重症、耐药菌检测和死亡率的发生率更高。对于 NHCAP,接受和未接受适当初始治疗的患者的成功率无差异(76.9% vs. 78.5%),30 天内死亡率也无差异(13.1% vs. 13.8%)。NHCAP 患者 30 天内死亡的危险因素为糖尿病[调整后的优势比(AOR)2.394,p=0.009]、白蛋白<2.5 g/dl(AOR 2.766,p=0.002)、A-DROP 非常严重(AOR 1.930,p=0.021)和影像学显示广泛肺炎(AOR 2.541,p=0.002)。在考虑初始治疗策略时,除了伦理问题外,NHCAP 中应考虑肺炎的严重程度而不是耐药菌的风险,以避免过度使用广谱抗菌药物。